Management Of Superficial Bladder Tumors: Group Study Comparing Epirubicin, Bacillus Calmette-Guerin (BCG), And BCG Plus Isoniazid

UroToday.com - Long-term efficacy results of EORTC GU group study 30911 comparing epirubicin, bacilus calmetteguerin (BCG), and BCG plus isoniazid in patients with intermediate and high risk stage Ta T1 papillary carcinoma of the bladderDr. Sylvester from the EORTC presented a study on the benefit of BCG relative to chemotherapy for long term endpoints, primarily in intermediate risk patients.

More: continued here

Filed under: Cancer on April 13th, 2008